login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
MIRUM PHARMACEUTICALS INC (MIRM) Stock News
USA
- NASDAQ:MIRM -
US6047491013
-
Common Stock
74.42
USD
-1.77 (-2.32%)
Last: 10/16/2025, 4:30:01 PM
74.42
USD
0 (0%)
After Hours:
10/16/2025, 4:30:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
MIRM Latest News, Press Relases and Analysis
All
Press Releases
20 days ago - By: Chartmill
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Combines Strong Growth Momentum with Bullish Technical Setup
5 hours ago - By: Benzinga
8 Analysts Assess Mirum Pharmaceuticals: What You Need To Know
6 days ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 days ago - By: Benzinga
- Mentions:
COCO
RIOT
SANA
KYIV
This Riot Platforms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
a month ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
a month ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study
2 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
2 months ago - By: Yahoo Finance
- Mentions:
MS
CMI
HSBC
LINE
...
Arm initiated, Adobe downgraded: Wall Street's top analyst calls
2 months ago - By: Zacks Investment Research
- Mentions:
TCRX
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
2 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
3 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
3 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 months ago - By: Yahoo Finance
- Mentions:
CBRL
EAT
GES
GOOS
...
UK's Thames Water set for over $13.5 billion rescue deal by Silver Point and Elliott, Bloomberg News reports
4 months ago - By: Zacks Investment Research
- Mentions:
MRNA
Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?
5 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer
5 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
5 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 months ago - By: Mirum Pharmaceuticals, Inc.
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL
5 months ago - By: Zacks Investment Research
- Mentions:
BEAM
ANIP
NTLA
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised
5 months ago - By: Zacks Investment Research
- Mentions:
SPRO
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
5 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
5 months ago - By: Zacks Investment Research
- Mentions:
CYTK
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
5 months ago - By: Zacks Investment Research
- Mentions:
TNGX
Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
6 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
6 months ago - By: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses
6 months ago - By: Stocktwits
- Mentions:
VTI
IWM
FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish
Please enable JavaScript to continue using this application.